Hydrocodone controlled-release - Purdue Pharma

Drug Profile

Hydrocodone controlled-release - Purdue Pharma

Alternative Names: HYD - Purdue Pharma; hydrocodone bitartrate extended-release - Purdue Pharma; Hydrocodone bitartrate once-daily - Purdue Pharma

Latest Information Update: 08 Sep 2015

Price : $50

At a glance

  • Originator Purdue Pharma
  • Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 08 Sep 2015 Purdue Pharma plans a phase II trial for Pain (In adolescents) in USA (NCT02542098)
  • 13 May 2015 Adverse events data from a phase III trial in Pain presented at the 34th Annual American Pain Society Scientific Meeting (APS-2015)
  • 26 Jan 2015 Launched for Pain in USA (PO)- First global launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top